Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes

doi:10.1016/0140-6736(90)90013-U

The Lancet

Volume 335, Issue 8682, 20 January 1990, Pages 147-149

https://doi.org/10.1016/0140-6736(90)90013-U Get rights and content

Abstract

The sensitivity and predictive value of islet-cell antibodies (ICA) for the future onset of insulin-dependent diabetes mellitus (IDDM) were determined in 719 first-degree relatives of IDDM patients. ICA were quantified in Juvenile Diabetes Foundation (JDF) units, by indirect immunofluorescence in serum samples taken during prospective follow-up of up to 10·5 years. The threshold of ICA detection was 4 JDF units. ICA were detected in the first sample of 26 (3·3%) of the relatives, compared with 12 (2·2%) of 540 controls (298 blood donors and 242 healthy children). ICA were detected in follow-up samples from a further 14 relatives. IDDM developed in 14 (35%) of the 40 relatives with detectable ICA at any time and in 2 (0·3%) relatives without detectable ICA. In all 5 relatives with peak ICA levels above 80 JDF units IDDM developed within follow-up of 7 years; survival without IDDM at 10 years was 27% among relatives with peak ICA levels of 20-80 JDF units and 82% for peak ICA levels of 4-20. The predictive value for IDDM development within 10 years ranged from 40% (threshold 4 JDF units) to 100% (80 JDF units) and the sensitivity from 31% (80 JDF units) to 88% (4 JDF units).

References (13)

Ac Tarn et al.
Predicting insulin-dependent diabetes
Lancet
(1988)
Gj Bruining et al.
Ten-year follow-up study of islet-cell antibodies and chilhood diabetes mellitus
Lancet
(1989)
Sj Cutler et al.
Maximum uutilization of the life table method in analyzing survival
J Chron Dis
(1958)
Gf Bottazzo et al.
Autoimmunity and diabetes: progress, consolidation and controversy
H. Gleichmann et al.
Islet cell and insulin autoantibodies in diabetes
Immunol Today
(1987)
E. Bonifacio et al.
Serum exchange and the use of dilutions have improved precision of measurement of islet cell antibodies
J Immunol Methods
(1988)

There are more references available in the full text version of this article.

Cited by (389)

Affinity purification of serum-derived anti-IA-2 autoantibodies in type 1 diabetes using a novel MBP-IA-2 fusion protein
2023, Biochemistry and Biophysics Reports
Citation Excerpt :
Particularly convincing are observations that onset of symptoms is concurrent with predominantly CD8+ T cell-mediated insulitis [5,6], and that both CD8+ and CD4+ T cells specific for islet-derived epitopes are present in islet-derived isolates from patients [6,7]. To date, considerations of humoral responses in T1D have focused primarily on the role of antibodies as diagnostic and/or prognostic markers of disease, and a considerable body of evidence supports the predictive value of serotyping autoantibody responses in at risk individuals [8–19]. While a correlation between the emergence of serum autoantibodies and conversion to clinical disease is suggestive of antibody-mediated pathogenesis, a direct relationship between the generation in individuals of autoantibodies to β cell targets and β cell loss has yet to be established [20].
Autoantibodies targeting epitopes contained within the intracellular domain (IC) of the protein phosphatase-like islet antigen 2 (IA-2) are a common marker of autoimmune type 1 diabetes (T1D), however the isolation of genuine, serum derived anti-IA-2 autoantibodies has proven challenging due to a lack of suitable bioassays. In the current study, an ELISA format was developed for affinity purification of human anti-IA-2ic autoantibodies utilizing a fusion protein (FP) incorporating maltose binding protein and the full-length IA-2IC domain. Using a T1D patient cohort validated for anti-IA-2ic autoantibodies by commercial ELISA, we demonstrate the MBP-IA-2ic FP ELISA detects serum anti-IA-2IC autoantibodies from 3 of 9 IA-2 positive patients. Further to this, a multi-plate MBP-IA-2ic FP ELISA protocol specifically affinity purifies IgG enriched for anti-IA-2ic autoantibodies. Interestingly, serum derived autoantibodies immobilised on the MBP-IA-2ic FP ELISA demonstrate increased Kappa light chain usage when compared to the respective total IgG derived from donor patients, suggesting a clonally restricted repertoire of anti-IA-2ic autoantigen specific B plasma cells is responsible for autoantibodies detect by the MBP-IA-2ic FP ELISA. This study is the first to demonstrate the generation of specific, genuine human derived anti-IA-2ic autoantibodies, thereby facilitating further investigation into the origin and functional significance of IA-2 autoantibodies in T1D.
100 Years of insulin: Lifesaver, immune target, and potential remedy for prevention
2021, Med
Citation Excerpt :
Importantly, it was IAAs that were present already in the age 9 months samples. Ezio Bonifacio, who had come from the Bottazzo school, which believed that ICA was the most important of the antibodies,76 was skeptical and measured ICA in these children. However, the data soon convinced him that insulin was indeed an important target, as case after case showed that IAAs were always present at that first positive sample (Figure 1).
In this review, we bring our personal experiences to showcase insulin from its breakthrough discovery as a life-saving drug 100 years ago to its uncovering as the autoantigen and potential cause of type 1 diabetes and eventually as an opportunity to prevent autoimmune diabetes. The work covers the birth of insulin to treat patients, which is now 100 years ago; the development of human insulin, insulin analogs, devices, and the way into automated insulin delivery; the realization that insulin is the primary autoimmune target of type 1 diabetes in children; novel approaches of immunotherapy using insulin for immune tolerance induction; the possible limitations of insulin immunotherapy; and an outlook on how modern vaccines could remove the need for another 100 years of insulin therapy.
Genetic predisposition, humans
2019, The Autoimmune Diseases
The translation from genetic knowledge to a molecular understanding of disease is contributing to the development of improved diagnostic and therapeutic products. Here, we briefly cover the localization of autoimmune disease-associated loci and examine recent progress in molecular understanding of autoimmune disease that has been facilitated by these approaches. We concentrate primarily on progress in the genetics of type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus and draw attention to parallels and contrasts between these diseases, other autoimmune diseases, and other immune diseases.
A cell-based assay for the detection of pathogenic anti-voltage-gated calcium channel autoantibodies in immunoglobulin G from patients with type 1 diabetes
2018, Journal of Immunological Methods
Citation Excerpt :
To date, considerations of humeral responses in T1D have focused on the role of antibodies as diagnostic and/or prognostic markers of disease. For example, since the publication over 20 years ago of seminal studies linking risk for T1D with the presence of serum antibodies against islet cell cytoplasmic antigens (Bonifacio et al., 1990; Schatz et al., 1994; Verge et al., 1996a; Verge et al., 1996b), a considerable body of research has confirmed the predictive value of serotyping autoantibody responses in at risk individuals (Ziegler et al., 1999; Steck et al., 2011; Parikka et al., 2012; Ziegler and Bonifacio, 2012; Ilonen et al., 2013; Krischer et al., 2015). To date, fine specification of the autoantibody responses in T1D has identified a number of β cell autoantigens, including glutamic acid decarboxylase (GAD65), insulinoma-associated autoantigen 2 (IA2) and zinc transporter 8 (ZnT8) (Atkinson et al., 2014).
Recent studies have postulated the presence of functional autoantibodies (Abs) against L-type voltage gated calcium channels (VGCCs) in the serum of patients with type 1 diabetes, with various proposed physiological consequences, both islet cell associated and extra-glandular. Arguably, the most potentially damaging effect reported for these Abs is induction of apoptosis in pancreatic beta (β) cells, yet a convincing pathogenic mechanism remains to be demonstrated. In the current study, we report an assay of reactive oxygen species (ROS) stress induction in the rat insulinoma cell line Rin A12, as determined by 2′, 7′-Dichlorofluorescein diacetate (DCF-DA) fluorescence detection by flow cytometry. We demonstrate that incubation of Rin A12 cells with immunoglobulin G (IgG) containing anti-VGCC activity from patients with T1D mediates a significant increase in ROS, with subsequent induction of apoptosis, as determined by positivity for annexin V expression. Neither T1D patient-derived IgG lacking anti-VGCC activity or IgG from healthy donors altered ROS or annexin V expression, indicating the new assay is specific for the detection of functional anti-VGCC Abs. Subsequent screening of IgG samples derived from individual patients indicated a prevalence of approximately 75% in a cohort of 20 patients with T1D. The new cell-based assay provides, for the first time, experimental evidence supporting a plausible pathophysiological mechanism underlying anti-VGCC Ab-mediated apoptosis induction in β cells. Additionally, the assay is a considerable advance on previously published methods for detecting and characterising the functional activity of anti-VGCC Abs in patient-derived samples.
Established and emerging biomarkers for the prediction of type 1 diabetes: A systematic review
2014, Translational Research
Type 1 diabetes (T1D) is an autoimmune disease with a prolonged and variable latent period that culminates in the destruction of pancreatic β-cells and the development of hyperglycemia. There is a need for diagnostic biomarkers to detect more accurately individuals with prediabetes to expedite targeting for prevention and intervention strategies. To assess the current ability to predict the insidious development of T1D, we conducted a comprehensive systematic review for established and prospective predictive markers of T1D using the Medline, OVID, and EMBASE databases. Resulting citations were screened for relevance to subject. Our research generated five major categories of markers that are either currently used or forthcoming: genetic, autoantibody, risk score quantification, cellular immunity, and β-cell function. The current standard used to assess T1D onset or predisposition focuses on autoimmune pathology and disease-associated autoantibodies. Research studies in general go beyond autoantibody screening and assess genetic predisposition, and quantitate risk of developing disease based on additional factors. However, there are few currently used techniques that assess the root of T1D: β-cell destruction. Thus, novel techniques are discussed with the potential to gauge degrees of β-cell stress and failure via protein, RNA, and DNA analyses.
Changing the landscape for type 1 diabetes: the first step to prevention
2019, The Lancet
Over several decades, studies have described the progression of autoimmune diabetes, from the first appearance of autoantibodies until, and after, the diagnosis of clinical disease with hyperglycaemia and insulin dependence. Despite the improved management of type 1 diabetes with exogenous insulin, most patients do not meet clinical glycaemic goals, and diabetes remains an important medical problem that affects children and adults. Clinical and preclinical studies have suggested strategies to prevent the diagnosis of type 1 diabetes in people at risk, but the outcomes of previous clinical trials have not met their primary endpoints of disease prevention or delay. The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease. This Series paper discusses how this clinical achievement raises new questions about for whom, and when, immunological strategies might be developed to prevent type 1 diabetes, and how to achieve this goal.

View all citing articles on Scopus

View full text

CLINICAL PRACTICEQuantification of islet-cell antibodies and prediction of insulin-dependent diabetes

Abstract

Lancet

Lancet

J Chron Dis

Autoimmunity and diabetes: progress, consolidation and controversy

Islet cell and insulin autoantibodies in diabetes

Immunol Today

Serum exchange and the use of dilutions have improved precision of measurement of islet cell antibodies

J Immunol Methods

$CLINICAL PRACTICE$
Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes